Democrats ask NIH for Xtandi march-in hearing

A group of 12 U.S. House and Senate Democrats sent a Xtandi enzalutamide from Astellas Pharma Inc. (Tokyo:4503).

In January, two patient advocacy groups asked NIH to exercise the rights for Xtandi, citing the drug's price as a barrier to its use. In Monday's letter, the lawmakers said Xtandi is not "available to U.S. residents on reasonable terms." The letter said a public hearing "would help provide insight into NIH's decision-making process on this case" and would "allow the public to engage in a dialogue" with HHS and NIH to understand their positions on use of march-in rights (see BioCentury Extra, Jan. 14). ...